Compare NWL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWL | GLUE |
|---|---|---|
| Founded | 1903 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1995 | 2021 |
| Metric | NWL | GLUE |
|---|---|---|
| Price | $4.91 | $17.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $4.97 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 9.0M | 842.1K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,742,200,000.00 | $123,672,000.00 |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.58 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | 11.14 | ★ 63.54 |
| 52 Week Low | $3.07 | $4.12 |
| 52 Week High | $6.64 | $25.77 |
| Indicator | NWL | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 49.49 |
| Support Level | $4.83 | $17.66 |
| Resistance Level | $5.14 | $18.66 |
| Average True Range (ATR) | 0.28 | 1.10 |
| MACD | 0.16 | -0.12 |
| Stochastic Oscillator | 94.72 | 44.71 |
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).